As we begin the new year, I would like to take a moment to thank you for your continued support and engagement with Mountain Valley MD.
On December 24, 2025, we issued our Year-End Business Update outlining the progress made across our three core platforms, Nutraceuticals, Agriculture, and Husbandry Animals & Aquatic Species. That update reflects a year defined by disciplined execution, extensive field validation, and deliberate decision-making as we worked to strengthen the commercial foundations of the Company. You can read the full media release on our website here.
In Nutraceuticals, 2025 was marked by continued advancement of our Quicksome™ platform through licensed products in market, ongoing formulation development, and an expanding pipeline addressing multiple human wellness applications. We believe these efforts have positioned the platform well as we move into additional licensing and product launches in 2026.
In Agriculture, the Agrarius™ program delivered some of the most compelling validation results we have seen to date. Across citrus, row crops, and pasture systems in Latin America, third-party monitored trials continued to demonstrate yield improvement, enhanced plant health, and improved resilience under environmental stress. In particular, the citrus results in Brazil, including outcomes observed in younger orchards, reinforce our belief that Agrarius™ has meaningful lifecycle relevance for growers facing increasing disease and climate-related challenges. We enter 2026 focused on translating this body of data into carefully structured commercial expansion.
In our husbandry and aquaculture business, we took a pragmatic view of our current licensing arrangements and began the process of reassessing how best to advance Soluvec™ with partners capable of executing at the scale required. While this has required difficult decisions, we believe a disciplined, capital-conscious approach is essential to creating long-term value.
As we enter 2026, our focus remains the same: building value through science-backed technologies, aligning with the right partners, and allocating capital responsibly. MVMD is positioned to confidently leverage the work we have completed over the past several years. We are operating with clear priorities, strong third-party validation across our technologies, and a disciplined execution framework. We believe this combination creates a meaningful opportunity to translate established progress into tangible commercial outcomes.
I appreciate the continued support and long-term commitment of our shareholders as we advance through this next phase of focused execution.
